An Open-Label, Multiple-Dose, Randomized, 2-Way Crossover Study In Healthy Volunteers To Determine The Steady-State Pharmacokinetics Of 660 Mg (2 X 330 Mg Tablets) Pregabalin Controlled Release Formulation Administered Following An Evening Meal Relative To The 300 Mg Of The Immediate Release Formulation Administered Twice Daily.
Phase of Trial: Phase I
Latest Information Update: 31 Jul 2014
At a glance
- Drugs Pregabalin (Primary)
- Indications Epilepsy; Neuropathic pain; Pain
- Focus Pharmacokinetics
- Sponsors Pfizer
- 17 Mar 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 03 Mar 2011 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 03 Mar 2011 Actual initiation date (Feb 2011) added as reported by ClinicalTrials.gov.